Your trusted destination for CME, CPD & Medical Education across the Middle East.
Qatar Precision Health Institute
Dr. Wadha A. Al-Muftah, MD, PhD is a physician-scientist and precision-health leader in Qatar. She is one of the founding leaders of the Qatar Genome Programme and has played a major role in developing Qatar's national genomics and precision-health initiatives.
She has served as Senior Director of the Genome Program at the Qatar Precision Health Institute (QPHI), Qatar Foundation, where she has led strategic initiatives involving genomic medicine, genome interpretation, clinical implementation, and the responsible return of genomic findings. In this role, she has worked closely with organizations including Hamad Medical Corporation, Sidra Medicine, the Ministry of Public Health, and Primary Health Care Corporation.
Dr. Al-Muftah earned her PhD in Clinical Research from Imperial College London through the Qatar Research Leadership Program. Her doctoral research investigated the genetic, epigenetic, and environmental determinants of type 2 diabetes in Qatari families. Her scientific work has contributed to research in population genomics, diabetes, pharmacogenomics, and precision medicine.
As Senior Director of the Qatar Genome Programme, she has been involved in the development of one of the region's major population-genomics initiatives. At the launch of QPHI, she reported that the Qatar Genome Programme had surpassed 40,000 whole genomes sequenced, supporting research and the implementation of precision healthcare in Qatar.
She has also contributed to the integration of genomics into clinical practice, including projects investigating pharmacogenetic testing and its impact on cardiovascular medications and clinical implementation of preemptive pharmacogenomics-guided prescribing.
Dr. Wadha A. Al-Muftah, MD, PhD, is a Qatari physician-scientist and healthcare executive recognized for her contributions to genomics, precision medicine, and translational research. She is the Chief Medical and Operations Officer at Qatar Precision Health Institute (QPHI) and is one of the founding leaders of the Qatar Genome Programme. Her work focuses on translating genetic and genomic discoveries into practical healthcare applications, supporting personalized medicine, and advancing national precision-health strategies in Qatar.
With more than 15 years of experience in medical research and healthcare innovation, Dr. Al-Muftah has helped develop initiatives that connect genomic research with clinical practice. Her work includes genomic interpretation, pharmacogenomics, population-level genetic research, and the responsible communication of genomic findings to patients and healthcare professionals.
She collaborates with healthcare and research organizations, including the Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, and the Primary Health Care Corporation. Her professional contributions aim to improve disease prevention, diagnosis, and treatment by incorporating genetic information into healthcare decision-making.
Qatar Precision Health Institute (QPHI), Qatar
Her doctoral research examined genetic, epigenetic, and environmental factors associated with type 2 diabetes in Qatari families.
As Chief Medical and Operations Officer, Dr. Al-Muftah contributes to the institute's strategic direction and operational leadership. Her work focuses on translating scientific discoveries into healthcare applications, supporting partnerships, and advancing precision-health initiatives across Qatar.
Dr. Al-Muftah has played a central role in developing the Qatar Genome Programme, a large-scale initiative investigating the genetic characteristics of the Qatari population and their implications for health.
Her responsibilities have included strategic planning, genomic research, genome interpretation, and initiatives to incorporate clinically relevant genetic findings into medical practice.
Her work has involved developing frameworks for genomic interpretation and clinical reporting, as well as supporting projects that integrate genomic discoveries into healthcare pathways. These initiatives help clinicians use genetic information to support diagnosis, treatment selection, and disease-risk assessment.
Dr. Al-Muftah has helped advance pharmacogenomics research in Qatar. Pharmacogenomics examines how genetic differences influence a person's response to medicines and can support more individualized medication selection and dosing.
Her work has included collaboration with national healthcare partners on studies exploring pharmacogenetic testing for cardiovascular medications.
This research examined inherited patterns of DNA methylation and their relationship with genetic regulation. It contributed to the understanding of epigenetic variation and its potential implications for human health.
This publication presented a methodological approach for genetic association testing using population and family-pedigree data, supporting research into the genetic factors underlying human traits.
This study examined public attitudes toward genomic testing in Qatar, providing evidence relevant to public engagement, consent, and the implementation of genomic medicine.
Dr. Al-Muftah contributed to collaborative research investigating genetic factors associated with COVID-19 susceptibility and severity. The research helped advance scientific understanding of host genetic variation and infectious disease outcomes.
Her broader research contributions include studies investigating genetic variation in the Qatari population and identifying associations between genomic characteristics and clinically relevant traits.
Dr. Al-Muftah's documented professional recognition includes her leadership positions in Qatar's national genomics and precision-health initiatives, her international research contributions, and her participation in scientific conferences and national health committees.
Specific named individual awards could not be reliably confirmed and are therefore not listed as established honors.

Maarefah Management
Maarefah Management